Downgrades Buy Hold X

ABCL AbCellera Biologics

The Benchmark Company

Upgrades Hold Buy X

ABCL AbCellera Biologics

The Benchmark Company

$9

Initiated Overweight X

ABCL AbCellera Biologics

KeyBanc Capital Markets

$6

Downgrades Buy Hold X

ABCL AbCellera Biologics

The Benchmark Company

Initiated Outperform X

ABCL AbCellera Biologics

Cowen

Initiated Buy X

ABCL AbCellera Biologics

Goldman

$30

Initiated Buy X

ABCL AbCellera Biologics

Truist

$29

Initiated Buy X

ABCL AbCellera Biologics

The Benchmark Company

$27

Initiated Overweight X

ABCL AbCellera Biologics

Piper Sandler

$33

Initiated Buy X

ABCL AbCellera Biologics

Berenberg

$53

Initiated Outperform X

ABCL AbCellera Biologics

BMO Capital Markets

$48

Initiated Outperform X

ABCL AbCellera Biologics

Credit Suisse

$52

Initiated Buy X

ABCL AbCellera Biologics

Stifel

$59

Initiated Outperform X

ABCL AbCellera Biologics

SVB Leerink

$45

ABCL  AbCellera Biologics Inc

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.